Synagis (Palivizumab) Drug Interactions: 11 Moderate
Synagis (Palivizumab) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Synagis. Always confirm against the full prescribing information.
100 interactions
Adenovirus type 7 vaccine live
The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Palivizumab.
Level 2 evidence
Anthrax vaccine
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Palivizumab.
Level 2 evidence
Bacillus calmette-guerin substrain tice live antigen
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Palivizumab.
Level 2 evidence
Chikungunya vaccine (live, attenuated)
The therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Palivizumab.
Level 2 evidence
Human adenovirus e serotype 4 strain cl-68578 antigen
The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Palivizumab.
Level 2 evidence
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Palivizumab.
Level 2 evidence
Aducanumab
The risk or severity of adverse effects can be increased when Palivizumab is combined with Aducanumab.
Level 2 evidence
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Palivizumab.
Level 2 evidence
Alirocumab
The risk or severity of adverse effects can be increased when Palivizumab is combined with Alirocumab.
Level 2 evidence
Amivantamab
The risk or severity of adverse effects can be increased when Palivizumab is combined with Amivantamab.
Level 2 evidence
Anifrolumab
The risk or severity of adverse effects can be increased when Palivizumab is combined with Anifrolumab.
Level 2 evidence
Ansuvimab
The risk or severity of adverse effects can be increased when Palivizumab is combined with Ansuvimab.
Synagis (Palivizumab) has 174 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Synagis (Palivizumab) has 0 major, 11 moderate, and 163 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Synagis. Always confirm against the full prescribing information.